{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:20:00Z","timestamp":1745036400533},"reference-count":0,"publisher":"Pakistan Medical Association","issue":"10 (Supple-08)","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pak Med Assoc"],"abstract":"<jats:p>Objective: To determine whether tocilizumab improved outcomes of patients hospitalised with severe coronavirusdisease-2019 cytokine storm syndrome.Method: The case-control study was conducted at Al-Yarmouk Teaching Hospital, Baghdad, and Al Shatra GeneralHospital, Thi Qar, Iraq, from September 2020 to March 2021, and comprised patients with severe acquiredrespiratory syndrome-corona virus-2 pneumonia who were not candidates for mechanical ventilation and receiveda single-dose intravenous infusion of tocilizumab 8mg\/kg in group A. The outcomes were compared with patientsin group B who received only standard care. Data was analysed using SPSS 26.Results: Of the 60 patients, 30(50%) were in group A; 22(73.3%) males and 8(26.7%) females with mean age56.63\u00b110.92 years. There were 30(50%) patients in control group B; 24(80%) males and 6(20%) females with meanage 54.8\u00b16.18 (p&gt;0.05). Group A showed significant changes compared to group B in the levels of interleukin-6,serum ferritin, D-dimer, procalcitonin, lymphocytes count and oxygen saturation (p&lt;0.05). Mortality rate was notsignificantly different between the groups (p&gt;0.05).Conclusions: Majority of the acute phase inflammatory markers were reduced significantly by treatment withtocilizumab.Key Words: Tocilizumab, fibrin, Interleukin, Procalcitonin, Cytokine, Infusions, Intravenous, Oxygen Saturation,Respiration, Artificial, Coronavirus, Lymphocytes, Ferritins<\/jats:p>","DOI":"10.47391\/jpma-bagh-16-25","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:22:22Z","timestamp":1728397342000},"page":"S111-S118","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Tocilizumab on the outcome of patients with severe COVID-19 with cytokine storm syndrome in a sample of Iraqi patients"],"prefix":"10.47391","volume":"74","author":[{"family":"Abdul Hameed Alqaseer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Alaa Kareem Dhayef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ammar Waham Ashor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26547","published-online":{"date-parts":[[2024,9,28]]},"container-title":["Journal of the Pakistan Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/jpma.org.pk\/index.php\/public_html\/article\/download\/21802\/3638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jpma.org.pk\/index.php\/public_html\/article\/download\/21802\/3638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T14:23:18Z","timestamp":1728656598000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpma.org.pk\/index.php\/public_html\/article\/view\/21802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":0,"journal-issue":{"issue":"10 (Supple-08)","published-online":{"date-parts":[[2024,9,28]]}},"URL":"https:\/\/doi.org\/10.47391\/jpma-bagh-16-25","relation":{},"ISSN":["0030-9982","0030-9982"],"issn-type":[{"type":"electronic","value":"0030-9982"},{"type":"print","value":"0030-9982"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}